Table of Contents
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral medications used primarily in the management of type 2 diabetes mellitus. They work by enhancing the body’s natural incretin system, thereby improving blood glucose regulation.
Introduction to DPP-4 Inhibitors
DPP-4 inhibitors, also known as gliptins, include drugs such as sitagliptin, saxagliptin, linagliptin, and alogliptin. They are often prescribed as monotherapy or in combination with other antidiabetic agents.
Mechanism of Action
The primary mechanism of DPP-4 inhibitors involves blocking the enzyme DPP-4, which is responsible for degrading incretin hormones. These hormones, mainly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play a crucial role in glucose homeostasis.
Role of Incretins
Incretins are released from the gut in response to food intake. They stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner and suppress glucagon release from alpha cells, reducing hepatic glucose production.
How DPP-4 Inhibitors Work
By inhibiting DPP-4, these drugs prolong the activity of endogenous incretins. Elevated levels of GLP-1 and GIP enhance insulin secretion when blood glucose levels are high and decrease glucagon secretion, leading to better glycemic control.
Clinical Significance
DPP-4 inhibitors offer several advantages, including oral administration, a low risk of hypoglycemia, and weight neutrality. They are particularly useful in patients who are unable to tolerate other antidiabetic medications.
Summary
Understanding the mechanism of DPP-4 inhibitors helps pharmacy students appreciate their role in diabetes management. By preventing the breakdown of incretins, these drugs effectively enhance the body’s natural response to elevated blood glucose levels.